TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00591006
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
Study: NCT00591006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
Study: NCT03018028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily
Study: NCT00611351
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00564681
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
Study: NCT03669263
Drug: Fentanyl buccal soluble film (FBSF)
Normalized name: fentanyl Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed.
Study: NCT02181335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02327546
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01563224
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00644033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
Study: NCT03779048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
Study: NCT02460900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00702741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Hyaluronan
Study: NCT01171859
Drug: Doxycycline + Tauroursodeoxycholic acid
Normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
Study: NCT04757506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02655315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo twice daily morning and evening. The treatment lasts nine months
Study: NCT02819921
Drug: Desvenlafaxine succinate 100mg
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pristiq 100mg
Study: NCT02819921
Drug: Desvenlafaxine succinate 50mg
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pristiq 50mg
Study: NCT02819921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00005780
Drug: EPOCH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH-R for 6 cycles
Study: NCT03258502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in capsules
Study: NCT02883569
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved medication such as ibuprofen, naxoprofen etc.
Study: NCT00240123
Drug: Benadryl versus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01271777
Drug: GFT505 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Study: NCT01271777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study: NCT02132416
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially intravenous administration and when tolerated oral slow-release pils will be used.
Study: NCT02621021
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
Study: NCT04225598
Drug: CAM2038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
Study: NCT00006016
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given transarterially (chemoembolization)
Study: NCT00003606
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01987609
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01987609
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01393561
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine + phenylephrine
Study: NCT01393561
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01899729
Drug: IMO-8400 Regimen 1
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
Study: NCT01899729
Drug: IMO-8400 Regimen 2
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
Study: NCT01899729
Drug: IMO-8400 Regimen 3
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
Study: NCT01899729
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline q wk x 12 wk by subcutaneous injection
Study: NCT01899729
Drug: IMO-8400 Regimen 4
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
Study: NCT03642873
Drug: Humibid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humibid® 1200 mg (single extended release) tablet
Study: NCT03642873
Drug: Humibid® and Hydrocodone Bitartrate tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
Study: NCT02234843
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care
Study: NCT04227470
Drug: HBM9161 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Study: NCT00841841
Drug: dipyrone and acetaminophen
Normalized name: acetaminophen / dipyrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
Study: NCT01643499
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01643499
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04533061
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens
Study: NCT02959229
Drug: Placebo (for Lactoferrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in form of distilled water
Study: NCT00909961
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02652585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
Study: NCT03593642
Drug: Continuous infusion of ropivacain in ESP catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
Study: NCT03593642
Drug: Continuous infusion of Iso Saline in ESP catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Iso Saline in ESP catheter to be the control group
Study: NCT05055752
Drug: Pharmaceutical-lipid aspirin (PL-ASA)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
Study: NCT01078779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
Study: NCT02182479
Drug: Berodual® via Respimat®, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182479
Drug: Berodual® via Respimat®, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182479
Drug: Berodual® via MDI, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182479
Drug: Placebo Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182479
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04255979
Drug: HY209
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Study: NCT02797184
Drug: KNO3, potassium nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
Study: NCT01158885
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Study: NCT04127669
Drug: OSU 6162
Normalized name: Osurnia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
Study: NCT04127669
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
Study: NCT03750968
Drug: Carotenoid Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
Study: NCT01350999
Drug: Eicosapentaenoic acid-ethyl (EPA)
Normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EPA-E capsules
Study: NCT00879021
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg by mouth ,twice a day for 49 weeks
Study: NCT00070694
Drug: MDL100.907
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03859869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally as capsules with a meal or snack
Study: NCT02220660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02778659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Study: NCT04325685
Drug: Bacteriophage
Normalized name: bacteriophages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
Study: NCT01571570
Drug: TMC435 150 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 150 mg TMC435 150 mg capsule
Study: NCT01571570
Drug: TMC435 150 mg oral suspension (20 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 150 mg TMC435 oral suspension
Study: NCT01571570
Drug: TMC435 150 mg oral solution (10 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 150 mg TMC435 oral solution
Study: NCT01571570
Drug: TMC435 150 mg capsule concept K
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 150 mg TMC435 capsule concept K
Study: NCT01571570
Drug: TMC435 150 mg capsule concept L
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 150 mg TMC435 capsule concept L
Study: NCT03582722
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
Study: NCT01678794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Study: NCT02772601
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03602911
Drug: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
Study: NCT03647423
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules
Study: NCT01733420
Drug: Biodentine pulpotomy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733420
Drug: Tempophore pulpotomy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00179621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matching to active study drug arms
Study: NCT00291616
Drug: Thymosin alpha1 & Pegylated Interferon-alpha2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
Study: NCT04199104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
Study: NCT04029649
Drug: Beta-1,3/1,6-D-Glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Study: NCT01395797
Drug: PIO
Normalized name: PIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 15, and 45 mg per day.
Study: NCT01395797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01997333
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02237417
Drug: Standard of Care Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
Study: NCT01500590
Drug: Renin-angiotensin system blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
Study: NCT01500590
Drug: non-renin angiotensin system blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
Study: NCT01908426
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00805350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Eplivanserin one tablet once a day
Study: NCT01095185
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
Study: NCT01095185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin placebo
Study: NCT03721068
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
Study: NCT03947827
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
Study: NCT01647789
Drug: CFG920
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00379535
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os
Study: NCT00242268
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00575185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets orally twice daily for 21 days.
Study: NCT02328014
Drug: ACP-319
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02172430
Drug: Tersigan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs of oxitropium three times daily via MDI
Study: NCT00001483
Drug: buproprion (Wellbutrin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03056209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, placebo
Study: NCT01110889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005984
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenously over 2 hours on day 1 and on days -7 and -6
Study: NCT00414635
Drug: Intermitent Dosing
Normalized name: CATH,INTERMIT,14FR MENTOR #3814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .
Study: NCT02421172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00991861
Drug: LAS41007 o.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topical application
Study: NCT00991861
Drug: LAS41007 b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, topical application
Study: NCT00991861
Drug: LAS106521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, topical application
Study: NCT04301375
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
Study: NCT02053597
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
Study: NCT01841281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
Study: NCT04527887
Drug: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
Study: NCT00966836
Drug: Prophylaxis with valganciclovir plus mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression